Mineralys’ strategic stock sale; Gilead, Shoreline partnership endsnews2025-09-03T15:22:35+00:00September 3rd, 2025|Endpoints News|
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engagernews2025-09-02T15:10:59+00:00September 2nd, 2025|Endpoints News|
Zydus to pursue PBC approval; Novocure terminates lung studynews2025-08-29T14:13:45+00:00August 29th, 2025|Endpoints News|
REMS tweaks for Travere’s Filspari; AstraZeneca stops early-phase cardio studynews2025-08-28T14:48:02+00:00August 28th, 2025|Endpoints News|
Verzenio’s survival benefit in early breast cancer; Another RemeGen Phase 3 winnews2025-08-27T14:48:23+00:00August 27th, 2025|Endpoints News|
Incannex’s stock rallies on anxiety disorder data; Appia Bio closes its doorsnews2025-08-26T14:51:38+00:00August 26th, 2025|Endpoints News|
MannKind to buy scPharmaceuticals for up to $360M; Arnatar launches with $52Mnews2025-08-25T15:08:15+00:00August 25th, 2025|Endpoints News|
Hong Kong’s IPO market is still active; Lighthouse’s $49M grant from NIHnews2025-08-22T14:47:15+00:00August 22nd, 2025|Endpoints News|
Sarepta refinances its debt; FDA delays decisions on Eylea HDnews2025-08-21T14:36:05+00:00August 21st, 2025|Endpoints News|
BiomX’s mid-stage cystic fibrosis trial put on clinical hold; Santen makes a deal with RemeGennews2025-08-19T14:53:45+00:00August 19th, 2025|Endpoints News|
